Protocol summary

Study aim
Evaluation effect of Agomelatine on sleep disorders in children and adolescents with ASD and comparing the results with Melatonin.
Design
Pts 3-18 with ASD and CSHQscore above 41: the intervention group:Agomelatin 25 mg HS, control group:Melatonin 3 ml for 3-6 1/2 tab and for 6-12 and one tab and for 12-18, 5 mg tab (1)HS, half hour before bed. study is a double blind clinical trial. Randomization in the form of permuted block randomization in blocks based on the sample size in sizes 2, 4, 6, 8 with a ratio of 1:1 in one or two groups, until the sample size is exhausted using the website https://icostatistics.shinyapps.io/ randlist/ will do.Sample size: Taking into the total sleep time,based on the reference, that before the treatment was 449 minutes and after the treatment was 532 minutes, with a standard deviation of 121, a power of 80% and an error of 5%, two groups of 35 pt plus 5, to avoid falling into each group
Settings and conduct
Pt in psychiatric clinics (3-18 ys old) in Imam Hossein Hospital with autism and sleep dis selecet and after informed consent,complete demographic questionnaire,CSHQ (scores above 41),GARS (for autism severity) and KSADS (for R/O comorbid disorder) so treatment starts for1month. At the end of1month CSHQ will be complete. parents,patient and psychiatrist that completing questionnaires (in both groups) will be blinded, and drugs will be delivered by clinic secretary, under hygienic conditions,in an anonymous and same packages.
Participants/Inclusion and exclusion criteria
CSHQ scor above 41 without sleep apnea and Seizure without ADHD,Dep,Anx Dont use sedative and immunosupresive drugs LFT belove 3 times normal without HTN
Intervention groups
Group1 tab Agomelatine 25 mg, group2 tab Melatonin 3mg for under 12 and Melatonin 5mg for above 12yrs on sleep dis in children and adolescents with ASD
Main outcome variables
Improve the score of CSHQ

General information

Reason for update
Acronym
ملاتونین بر خواب اوتیسم
IRCT registration information
IRCT registration number: IRCT20230607058407N1
Registration date: 2023-10-30, 1402/08/08
Registration timing: retrospective

Last update: 2023-10-30, 1402/08/08
Update count: 0
Registration date
2023-10-30, 1402/08/08
Registrant information
Name
Nezhla Mostafeenezhad
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 21 7755 1023
Email address
dr.nejla.mostafeenezhad@gmail.com
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2023-07-11, 1402/04/20
Expected recruitment end date
2023-10-22, 1402/07/30
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Evaliuation of the effect of Melatonin and Agomelatin on sleep problem in children and adolescent with Autism spactrum disorder
Public title
Evaliuation of the effect of Melatonin and Agomelatin on sleep problem in children and adolescent with Autism spactrum disorder
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
children and adolescents with autism spectrum disorder and with sleep disorders
Exclusion criteria:
doubt to sleep apnea resistant patiants
Age
From 3 years old to 18 years old
Gender
Both
Phase
3
Groups that have been masked
  • Participant
  • Care provider
  • Investigator
  • Outcome assessor
  • Data analyser
Sample size
Target sample size: 80
Randomization (investigator's opinion)
Randomized
Randomization description
Randomization: All eligible subjects will be randomly assigned to one of the two groups receiving melathionine and agomelatine with a ratio of 1:1. The randomization method will be permuted block randomization, which blocks will be done based on the sample size in sizes 2, 4, 6, 8 until the sample size is exhausted using the website https://icostatistics.shinyapps.io/randlist/. Patients will be included in each group based on the determined sample size and based on the list of randomized individuals (along with a specific research code for each individual)
Blinding (investigator's opinion)
Double blinded
Blinding description
In compliance with health principles,the melatonin and agomelatonin tablets will be removed from the original drug envelope by the clinic secretary and will be given to the parents in the nameless envelope according to the randomization table. With this method, the patient, parent, researcher and statistician do not know the type of medicine used by each patient.
Placebo
Not used
Assignment
Parallel
Other design features
ASD severity will assessed and depression ,anxiety and ADHD will R/O.

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethicscimmittee of Shahid Beheshti University of Medical Sciences
Street address
Shahid Beheshti university of medical science,Medical school, velenjak, Koodakyar Avn, DaneshjooAvn,Tehran
City
Tehran
Province
Tehran
Postal code
1985717443
Approval date
2023-06-03, 1402/03/13
Ethics committee reference number
IR.SBMU.MSP.REC.1402.086

Health conditions studied

1

Description of health condition studied
Autism spectrum disorder
ICD-10 code
F84.0
ICD-10 code description
Autistic disorder

2

Description of health condition studied
sleep disorder
ICD-10 code
G47.0
ICD-10 code description
Insomnia

Primary outcomes

1

Description
change the score of children sleep habits questannaire
Timepoint
at the beggining and 1 month later
Method of measurement
children sleep habits questannaire

Secondary outcomes

empty

Intervention groups

1

Description
Control group: slow-release melatonin tab: half a tablet of 3 mg for the age of 3-5 years, one tablet of 3 mg for the age of 6-12, and melatonin 5mg for the age of 12-18, half an hour before bedtime
Category
Treatment - Drugs

2

Description
Intervention group: Agumelatine tab imediate release 25 mg ,one tablet at night ,half an hour before sleep
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
Imamhosein hospital
Full name of responsible person
Katayon Razjouyan
Street address
Madani st Imamhosein hospital
City
Tehran
Province
Tehran
Postal code
167763141
Phone
+98 21 7755 1023
Email
Dr.nejla.mostafeenezhad@gmail.com

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
Dr Afshin Zarghi
Street address
Madani st,Imamhosein hospital, child and adolescents psychiatry ward
City
Tehran
Province
Tehran
Postal code
1617763141
Phone
+98 21 7755 1023
Email
zarghi@sbmu.ac.ir
Grant name
no
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Shahid Beheshti University of Medical Sciences
Proportion provided by this source
50
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
Nezhla Mostafeenezhad
Position
Specialist Assistant
Latest degree
Specialist
Other areas of specialty/work
Psychiatrics
Street address
Madani st, Imam Hosein Hospital
City
Tehran
Province
Tehran
Postal code
1617763141
Phone
+98 21 7755 1023
Email
Dr.nejla.mostafeenezhad@gmail.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
Dr Nezhla Mostafeenezhad
Position
Child and Adolescents Psychiatry Residency
Latest degree
Specialist
Other areas of specialty/work
Psychiatrics
Street address
Madani st, Imamhosein Hospital, Child and Adolescents Psychiatry Ward
City
Tehran
Province
Tehran
Postal code
1617763141
Phone
+98 21 7755 1023
Email
Dr.nejla.mostafeenezhad@gmail.com

Person responsible for updating data

Contact
Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
Dr Nezhla Mostafeenezhad
Position
Specialist Assistant
Latest degree
Specialist
Other areas of specialty/work
Psychiatrics
Street address
Madani st, Imamhosein Hospital
City
Tehran
Province
Tehran
Postal code
1617763141
Phone
+98 21 7755 1023
Email
Dr.nejla.mostafeenezhad@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available
Study Protocol
Undecided - It is not yet known if there will be a plan to make this available
Statistical Analysis Plan
No - There is not a plan to make this available
Informed Consent Form
Undecided - It is not yet known if there will be a plan to make this available
Clinical Study Report
Undecided - It is not yet known if there will be a plan to make this available
Analytic Code
Undecided - It is not yet known if there will be a plan to make this available
Data Dictionary
Undecided - It is not yet known if there will be a plan to make this available
Title and more details about the data/document
The results of the data analysis will be published in the form of an article
When the data will become available and for how long
After publication in domestic or foreign magazines
To whom data/document is available
no body
Under which criteria data/document could be used
---
From where data/document is obtainable
--
What processes are involved for a request to access data/document
--
Comments
Loading...